Evidence map›Paper›PMID 37557116›Full record

ArticleDermatology practical & conceptual2023

Smart e-Skin Cancer Care in Europe During and after the Covid-19 Pandemic: a Multidisciplinary Expert Consensus.

Josep Malvehy, Brigitte Dreno, Enric Barba, Thomas Dirshka, Emilio Fumero, Christian Greis, Girish Gupta, Francesco Lacarrubba, Giuseppe Micali, David Moreno and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology practical & conceptual, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 6 countries.

Josep MalvehyDermatology Department. Hospital Clinic of Barcelona, Spain.
Brigitte DrenoDepartment of Dermatolo-Cancerology, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France.
Enric BarbaSpanish Melanoma Association, Barcelona, Spain.
Thomas DirshkaCentroderm Clinic, Wuppertal, and Faculty of Health, University Witten-Herdecke, Witten, Germany.
Emilio FumeroAlmirall R&D, St. Feliu de Llobregat, Spain.
Christian GreisDepartment Dermatology, University Hospital of Zurich, Zurich, Switzerland.
Girish GuptaUniversity Department of Dermatology, Edinburgh Royal Infirmary, Lauriston Building, Edinburgh, UK.
Francesco LacarrubbaDermatology Clinic, University of Catania, Catania, Italy.
Giuseppe MicaliDermatology Clinic, University of Catania, Catania, Italy.
David MorenoDermatology Department, University Hospital Virgen Macarena, Seville, Spain.
Giovanni PellacaniDermatology Department. Università degli Studi di Roma La Sapienza. Roma, Italy.
Laura Sampietro-ColomAssessment of Innovations and New Technologies Unit, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.
Alexander StratigosDepartment of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodestrian University of Athens, Athens, Greece.
Susanna PuigDermatology Department. Hospital Clinic of Barcelona, Spain.
Centre for Biomedical Network Research on Rare Diseases · ESHospital Universitario Virgen Macarena · ESUniversity of Catania · ITAlmirall (Spain) · ESEdinburgh Royal Infirmary · GBNational and Kapodistrian University of Athens · GRUniversitat de Barcelona · ESUniversity Hospital of Zurich · CHWitten/Herdecke University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMelanoma is the deadliest of all the skin cancers and its incidence is increasing every year in Europe. Patients with melanoma often present late to the specialist and treatment is delayed for many reasons (delay in patient consultation, misdiagnosis by general practitioners, and/or limited access to dermatologists). Beyond this, there are significant inequalities in skin cancer between population groups within the same country and between countries across Europe. The emergence of the COVID-19 pandemic only aggravated these health deficiencies.

objectivesThe aim was to create an expert opinion about the challenges in skin cancer management in Europe during the post COVID-19 acute pandemic and to identify and discuss the implementation of new technologies (including e-health and artificial intelligence defined as "Smart Skin Cancer Care") to overcome them.

methodsFor this purpose, an ad-hoc questionnaire with items addressing topics of skin cancer care was developed, answered independently and discussed by a multidisciplinary European panel of experts comprising dermatologists, dermato-oncologists, patient advocacy representatives, digital health technology experts, and health technology assessment experts.

resultsAfter all panel of experts discussions, a multidisciplinary expert opinion was created.

conclusionsAs a conclusion, the access to dermatologists is difficult and will be aggravated in the near future. This fact, together with important differences in Skin Cancer Care in Europe, suggest the need of a new approach to skin health, prevention and disease management paradigm (focused on integration of new technologies) to minimize the impact of skin cancer and to ensure optimal quality and equity.

Identifiers

PMID37557116
PMCPMC10412091
OpenAlexW4385457192

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.